INS and hepatobiliary disorder: Notably, ceritinib and alectinib both showed elevated hepatobiliary disorder signals, likely attributable to ceritinib’s dual inhibition of insulin and IGF-1 receptors, which can disrupt hepatic metabolic homeostasis [27].